A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-491 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension.

Trial Profile

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-491 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Azilsartan medoxomil (Primary) ; Olmesartan medoxomil
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 25 Aug 2016 Primary endpoint (Change From Baseline in Sitting Clinic Diastolic Blood Pressure) has been met,according to the results published in the Journal of Clinical Hypertension (Greenwich).
    • 25 Aug 2016 Results published in the Journal of Clinical Hypertension (Greenwich) (2016).
    • 23 Jun 2009 Actual patient number amended from 442 to 449 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top